Mesoblast to Seek FDA Approval for Ryoncil®
Company Announcements

Mesoblast to Seek FDA Approval for Ryoncil®

Mesoblast (MESO) has released an update.

Mesoblast Limited, a global leader in allogeneic cellular medicines, announced it will submit a Biologics License Application for its product Ryoncil® to the FDA next week, targeting the treatment of children with steroid-refractory acute graft versus host disease. The company boasts a robust intellectual property portfolio and a range of late-stage product candidates aimed at severe inflammatory conditions. Mesoblast’s off-the-shelf cell therapy products, including remestemcel-L for inflammatory diseases, are poised for rapid availability to patients globally.

For further insights into MESO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMesoblast Poised for Breakthroughs in Cellular Medicine
TheFlyMesoblast management to meet with Maxim
TipRanks Auto-Generated NewsdeskMesoblast Advances Cellular Medicines Amid FDA Hopes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App